Claims

1. A selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, and ii) a selective estrogen degrader, or a pharmaceutically acceptable salt thereof, to said subject.

2. Use of a selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a subject, wherein i) said selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, and ii) a selective estrogen degrader, or a pharmaceutically acceptable salt thereof, are to be administered to the subject separately, sequentially or simultaneously.

3. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use according to claim 1 or the use according to claim 2, wherein the cancer is:
a) breast cancer;
b) ER+ breast cancer;
c) ER+ breast cancer which is BRCA1/2m; or
d) ER+ breast cancer which is HR deficient.

4. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to any of claims 1 to 3, wherein the selective PARP inhibitor is AZD5305.

5. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to any one of claims 1 to 4, wherein the selective estrogen degrader is camizestrant.

6. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to either claim 4 or claim 5, wherein AZD5305 is to be administered once daily.

7. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 6, wherein AZD5305 is to be administered in a dose of up to about 60 mg per day.

8. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 7, wherein AZD5305 is to be administered in a dose of 60 mg per day.

9. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 6, wherein AZD5305 is to be administered in a dose of 20 mg per day.

10. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to any one of claims 6 to 9, wherein the selective estrogen degrader is camizestrant and is to be administered once daily.

11. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 9, wherein camizestrant is to be administered in a dose of about 50 mg to about 150 mg once a day.

12. The selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 10, wherein camizestrant is to be administered in a dose of 75 mg once a day.

13. A selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said selective estrogen degrader, or a pharmaceutically acceptable salt thereof, and ii) a selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, to said subject.

14. Use of a selective estrogen degrader, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a subject, wherein i) said selective estrogen degrader, or a pharmaceutically acceptable salt thereof, and ii) a selective PARP1 inhibitor, or a pharmaceutically acceptable salt thereof, are to be administered to said subject separately, sequentially or simultaneously.

15. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use according to claim 12 or the use according to claim 13, wherein the cancer is:

a) breast cancer;

b) ER+ breast cancer;

c) ER+ breast cancer which is BRCA1/2m; or
d) ER+ breast cancer which is HR deficient.

16. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to any of claim 13 to claim 15, wherein the selective PARP inhibitor is AZD5305.

17. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to any one of claims 13 to 16, wherein the selective estrogen degrader is camizestrant.

18. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to either claim 16 or claim 17, wherein AZD5305 is to be administered once daily.

19. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 18, wherein AZD5305 is to be administered in a dose of up to about 60 mg per day.

20. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 19, wherein AZD5305 is to be administered in a dose of 60 mg per day.

21. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 19, wherein AZD5305 is to be administered in a dose of 20 mg per day.

22. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to any one of claims 17 to 21, wherein the selective estrogen degrader is camizestrant and is to be administered once daily.

23. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 18, wherein camizestrant is to be administered in a dose of about 50 mg to about 150 mg once a day.

24. The selective estrogen degrader, or a pharmaceutically acceptable salt thereof, for use or the use according to claim 19, wherein camizestrant is to be administered in a dose of 75 mg once a day.

25. A pharmaceutical product comprising i) a selective PARP1 inhibitor or a pharmaceutically acceptable salt thereof, and ii) a selective estrogen degrader or a pharmaceutically acceptable salt thereof.

26. The pharmaceutical product according to claim 25, wherein the selective PARP1 inhibitor is AZD5305.

27. The pharmaceutical product according to either claim 25 or 26, wherein the selective estrogen degrader is camizestrant.

28. The pharmaceutical product according to claims 25-27 for use in therapy.